PO.TB10.11 · 肿瘤生物学
胰腺肿瘤表达的生长因子在人成纤维细胞中激活一种与不良预后相关的神经样程序
Pancreatic tumor expressed growth factors activate a neural-like program in human fibroblasts which is associated with poor prognosis
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
胰腺导管腺癌(PDAC)是最具侵袭性的癌症之一,5年生存率低于14%。肿瘤微环境(TME)在PDAC进展中发挥核心作用,主要由癌症相关成纤维细胞(CAFs)组成,同时伴有较少量的肿瘤、神经和免疫细胞群。近期,在PDAC TME中鉴定出一群表现出神经样程序的基质细胞,其存在与不良结局和化疗耐药相关。然而,这些神经样细胞的起源及其在肿瘤进展中的作用仍不明确。在一个使用Xenium空间转录组学的相关项目中,我们发现一些CAFs表达这种神经样程序,并常聚集于肿瘤细胞附近。基于此,我们假设这种程序可通过暴露于PDAC细胞分泌的生长因子而在CAFs中被激活。为验证我们的Xenium发现,我们对32例跨疾病分期的宏切PDAC样本进行了循环免疫荧光,对肿瘤、成纤维细胞和神经标志物进行染色。这些分析显示,一部分CAFs表达神经样程序。无偏聚类进一步表明,神经程序激活的CAFs密度越高,以及它们与肿瘤细胞的距离越近,与疾病进展相关。接下来,我们在体外研究了肿瘤细胞与人细胞系成纤维细胞中神经样程序之间的关系。当与PDAC细胞共培养时,即使不添加生长因子,成纤维细胞也促进肿瘤生长并激活神经标志物,表明肿瘤细胞可驱动这种重编程。经吉西他滨处理后,神经程序激活的成纤维细胞比正常成纤维细胞存活得更好,而肿瘤细胞仍然敏感。这提示神经样程序增强了成纤维细胞的存活,而非直接促进肿瘤化疗耐药,可能支持残留肿瘤细胞的增殖,尽管这需要进一步验证。最后,我们旨在鉴定神经样程序激活的潜在机制。Xenium数据突出了几种神经相关生长因子作为候选因子。将人成纤维细胞系暴露于这些因子的组合显示,其中两种足以诱导神经标志物。对质谱流式数据的重新分析鉴定出所涉及的下游信号通路,抑制剂的使用证实了这些发现。总体而言,我们的工作表明PDAC细胞可通过生长因子介导的信号在成纤维细胞中激活一种神经样程序,并提示这种可塑性是肿瘤进展和治疗耐药的促成因素。进一步剖析这一过程可能揭示新的干预点,以限制CAF对肿瘤的支持并增强PDAC中的化疗有效性。
查看英文原文 English abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, with a 5-year survival of less than 14%. The tumor microenvironment (TME) plays a central role in PDAC progression and is composed primarily of cancer-associated fibroblasts (CAFs), together with smaller populations of tumor, nerve, and immune cells. Recently, a population of stromal cells exhibiting a neural-like program has been identified within the PDAC TME, and its presence correlates with poor outcomes and chemoresistance. However, the origin of these neural-like cells and their role in tumor progression remain unclear. In a related project using Xenium spatial transcriptomics, we found that some CAFs express this neural-like program and often cluster near tumor cells. Based on this, we hypothesized that this program can be activated in CAFs through exposure to growth factors secreted by PDAC cells.To validate our Xenium findings, we performed cyclic immunofluorescence on 32 macrodissected PDAC samples across disease stages, staining for tumor, fibroblast, and neural markers. These analyses showed that a subset of CAFs expresses a neural-like program. Unbiased clustering further demonstrated that higher densities of neural-program-activated CAFs, as well as their closer proximity to tumor cells, are associated with disease progression. Next, we investigated in vitro the relationship between tumor cells and the neural-like program in human cell line fibroblasts. When co-cultured with PDAC cells, fibroblasts promoted tumor growth and activated neural markers even without added growth factors, indicating that tumor cells can drive this reprogramming. After gemcitabine treatment, neural-program-activated fibroblasts survived better than normal fibroblasts, while tumor cells remained sensitive. This suggests that the neural-like program enhances fibroblast survival rather than directly promoting tumor chemoresistance, potentially supporting the proliferation of residual tumor cells, although this requires further validation.Finally, we aimed to identify the mechanisms underlying neural-like program activation. Xenium data highlighted several neural-associated growth factors as candidates. Exposing human fibroblast cell lines to combinations of these factors showed that two of them were sufficient to induce neural markers. Re-analysis of mass cytometry data identified the downstream signaling pathways involved, and the use of inhibitors confirmed these findings.Overall, our work shows that PDAC cells can activate a neural-like program in fibroblasts through growth factor-mediated signaling and implicates this plasticity as a contributor to tumor progression and treatment resistance. Further dissecting this process could reveal new intervention points to limit CAF support for the tumor and enhance chemotherapy effectiveness in PDAC.
利益披露 Disclosure
M. I. Ibanez Rios, None..
M. Batardiere, None..
A. Archambault-Marsan, None..
E. Dianati Ajibisheh, None..
V. Trinh, None..
D. J. F. Knapp, None.